Abstract
Pulmonary infection is a disease-causing death worldwide that attacks the lower airway organs by various kinds of microorganisms. Antibacterial or antiviral has been used for the therapy of lung infections, but up to this point the case of resistance to drugs is still high. Therefore, to overcome this problem, it is necessary to develop new drugs, namely natural drugs. However, natural drugs have limitations (physicochemical properties and low bioavailability), so the development of inhalation natural drug delivery systems is needed. Various studies have been conducted to develop inhalation natural drug delivery systems such as microparticles, microsponges, nanoparticles, nanomicelles, etc. The use of these delivery systems has been shown to have a positive impact on the physico-chemical properties, bioavailability and antibiotic/antiviral activity of natural drugs through targeted delivery of lungs both in-vitro and in-vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
